Edition:
United Kingdom

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

5.39USD
17 Aug 2018
Change (% chg)

$-0.16 (-2.88%)
Prev Close
$5.55
Open
$5.55
Day's High
$5.55
Day's Low
$5.39
Volume
825,347
Avg. Vol
640,581
52-wk High
$7.66
52-wk Low
$4.34

Select another date:

Wed, May 30 2018

Photo

TherapeuticsMD's therapy for menopause-related condition gets approval

Women's healthcare company TherapeuticsMD Inc won its first-ever U.S. approval on Wednesday with the drug regulator clearing its hormone therapy for a painful condition triggered by menopause after rejecting it a year earlier.

UPDATE 2-TherapeuticsMD's therapy for menopause-related condition gets approval

* Shares volatile; last down 2 pct (Adds analyst, CEO comment, share movement)

FDA approves TherapeuticsMD's hormone therapy

May 30 The U.S. Food and Drug Administration approved TherapeuticsMD Inc's hormone therapy for a painful condition triggered by menopause, the women's health company said on Wednesday.

BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11

* THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR

* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR

BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR

BRIEF-TherapeuticsMD Q4 Loss Per Share $0.10

* THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Select another date: